Differences in evidentiary requirements for oncology drug effectiveness assessments among six European health technology assessment bodies — can alignment be improved?-Reference-Cited by-同舟云学术

Differences in evidentiary requirements for oncology drug effectiveness assessments among six European health technology assessment bodies — can alignment be improved?

Published:2023-09-28 Issue:2 Volume:24 Page:251-265
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Wolters Sharon¹²,de Jong Lisa A²^ORCID,Jansen Christel³⁴,Jansman Frank GA⁵⁶,Postma Maarten J²⁷⁸

Affiliation:

1. Asc Academics B.V, Groningen, The Netherlands

2. Department of Health Sciences, University of Groningen, University Medical Center, Groningen, Groningen, The Netherlands

3. Vintura Consultancy, Baarn, the Netherlands

4. Inbeoo Ltd (current), London, The UK

5. Department of Clinical Pharmacy, Deventer Teaching Hospital, Deventer, the Netherlands

6. Department of Pharmacotherapy, Pharmacoepidemiology and Pharmacoeconomics, Groningen, Research Institute of Pharmacy (GRIP), University of Groningen, Groningen, the Netherlands

7. Department of Economics, Econometrics & Finance, University of Groningen, Groningen, the Netherlands

8. Center of Excellence in Higher Education for Pharmaceutical Care Innovation, Padjadjaran University, Bandung, Indonesia

Funder

European Federation of Pharmaceutical Industries and Associations

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2023.2263166

Reference21 articles.

1. IQVIA. EFPIA patients W.A.I.T. Indicator 2021 survey [Internet]. 2022 [cited 2023 Aug 21]. Available from: https://www.efpia.eu/media/676539/efpia-patient-wait-indicator_update-july-2022_final.pdf.

2. How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory‐HTA parallel scientific advice

3. Relative effectiveness assessments of oncology medicines for pricing and reimbursement decisions in European countries

4. Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries

5. Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expert review of pharmacoeconomics and outcomes research: high impact articles from 2023;Expert Review of Pharmacoeconomics & Outcomes Research;2024-04-09